Sector ratings Protalix BioTherapeutics, Inc.

Stocks

Market Closed - NYSE 00:00:00 02/10/2026 +04			5-day change	1st Jan Change
2.680 ^USD	-2.90%		-4.29%	+48.89%

09-16	Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
08-12	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PROTALIX BIOTHERAPEUTICS, INC.	222M	-	-	-	-
ELI LILLY AND COMPANY	1,031B		A
JOHNSON & JOHNSON	638B		BBB
ABBVIE INC.	462B		AAA		-
MERCK & CO., INC.	359B		A
ROCHE HOLDING AG	335B		AA
NOVARTIS AG	273B		AAA
ASTRAZENECA PLC	253B		A
AMGEN INC.	228B		A
GILEAD SCIENCES, INC.	185B		AA
NOVO NORDISK A/S	170B		BBB
PFIZER INC.	163B		A
VERTEX PHARMACEUTICALS INCORPORATED	133B		AA
BRISTOL-MYERS SQUIBB COMPANY	127B		A
MCKESSON CORPORATION	99.55B	-	AA	-	-
GSK PLC	97.46B		AA
SANOFI	98.83B		A
MODERNA, INC.	76.88B	-	BBB	-	-
REGENERON PHARMACEUTICALS, INC.	75.72B		BBB
MERCK KGAA	68.18B		AAA
Average	243.67B		AA
Weighted average by Cap.			AA